WP
XFOR icon

Woodline Partners’s X4 Pharmaceuticals XFOR Stock Holding History

Woodline Partners’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.68M Hold
1,001,095
– – 0.01% 705
2026
Q1 		$4.13M Buy
1,001,095
+240
+0% +$899 0.02% 691
2025
Q4 		$4M Buy
+1,000,855
New +$3.64M 0.02% 671

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners's XFOR Position: Q2 2026 in Review

Woodline Partners held its X4 Pharmaceuticals (XFOR) position steady in Q2 2026 at 1,001,095 shares worth $4.68M. The position accounts for 0.01% of the portfolio, ranked #705.

Woodline Partners first reported a position in XFOR in Q4 2025 and has held it in 3 quarters since. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Woodline Partners held 1,001,095 shares of X4 Pharmaceuticals worth $4.68M as of Q2 2026.
  • Woodline Partners left its X4 Pharmaceuticals share count unchanged in Q2 2026.
  • X4 Pharmaceuticals made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #705 holding.
  • Woodline Partners first reported a position in X4 Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.